205 related articles for article (PubMed ID: 12052143)
1. Arylamine N-acetyltransferases and drug response.
Meisel P
Pharmacogenomics; 2002 May; 3(3):349-66. PubMed ID: 12052143
[TBL] [Abstract][Full Text] [Related]
2. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
3. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
Sim E; Fakis G; Laurieri N; Boukouvala S
Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics, biochemistry, toxicology, microbiology and cancer research in one go.
Rodrigues-Lima F; Dairou J; Laurieri N; Busi F; Dupret JM
Pharmacogenomics; 2011 Aug; 12(8):1091-3. PubMed ID: 21843062
[TBL] [Abstract][Full Text] [Related]
5. Regulation of arylamine N-acetyltransferases.
Butcher NJ; Tiang J; Minchin RF
Curr Drug Metab; 2008 Jul; 9(6):498-504. PubMed ID: 18680469
[TBL] [Abstract][Full Text] [Related]
6. Comparative genomic and phylogenetic investigation of the xenobiotic metabolizing arylamine N-acetyltransferase enzyme family.
Glenn AE; Karagianni EP; Ulndreaj A; Boukouvala S
FEBS Lett; 2010 Jul; 584(14):3158-64. PubMed ID: 20621844
[TBL] [Abstract][Full Text] [Related]
7. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
[TBL] [Abstract][Full Text] [Related]
8. The impact of genetic polymorphisms in risk assessment of drugs.
Poulsen HE; Loft S
Arch Toxicol Suppl; 1994; 16():211-22. PubMed ID: 8192584
[No Abstract] [Full Text] [Related]
9. Polymorphic NATs and cancer predisposition.
Hirvonen A
IARC Sci Publ; 1999; (148):251-70. PubMed ID: 10493262
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of the arylamine N-acetyltransferases.
Butcher NJ; Boukouvala S; Sim E; Minchin RF
Pharmacogenomics J; 2002; 2(1):30-42. PubMed ID: 11990379
[TBL] [Abstract][Full Text] [Related]
11. Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function.
Sim E; Pinter K; Mushtaq A; Upton A; Sandy J; Bhakta S; Noble M
Biochem Soc Trans; 2003 Jun; 31(Pt 3):615-9. PubMed ID: 12773167
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA; Zanger UM
Annu Rev Pharmacol Toxicol; 1997; 37():269-96. PubMed ID: 9131254
[TBL] [Abstract][Full Text] [Related]
13. The Bacillus anthracis arylamine N-acetyltransferase ((BACAN)NAT1) that inactivates sulfamethoxazole, reveals unusual structural features compared with the other NAT isoenzymes.
Pluvinage B; Li de la Sierra-Gallay I; Kubiak X; Xu X; Dairou J; Dupret JM; Rodrigues-Lima F
FEBS Lett; 2011 Dec; 585(24):3947-52. PubMed ID: 22062153
[TBL] [Abstract][Full Text] [Related]
14. [Importance of genetically determined acetylation of drugs and xenobiotics in pathogenesis of neoplasms].
Niewiński P; Orzechowska-Juzwenko K
Pol Merkur Lekarski; 1997 Jan; 2(9):231-5. PubMed ID: 10907039
[TBL] [Abstract][Full Text] [Related]
15. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.
Sugamori KS; Wong S; Gaedigk A; Yu V; Abramovici H; Rozmahel R; Grant DM
Mol Pharmacol; 2003 Jul; 64(1):170-9. PubMed ID: 12815173
[TBL] [Abstract][Full Text] [Related]
16. The pharmacogenetics of NAT: structural aspects.
Pompeo F; Brooke E; Kawamura A; Mushtaq A; Sim E
Pharmacogenomics; 2002 Jan; 3(1):19-30. PubMed ID: 11966400
[TBL] [Abstract][Full Text] [Related]
17. Acrolein, an α,β-unsaturated aldehyde, irreversibly inhibits the acetylation of aromatic amine xenobiotics by human arylamine N-acetyltransferase 1.
Bui LC; Manaa A; Xu X; Duval R; Busi F; Dupret JM; Rodrigues-Lima F; Dairou J
Drug Metab Dispos; 2013 Jul; 41(7):1300-5. PubMed ID: 23633528
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous genotyping of nine polymorphisms in xenobiotic-metabolizing enzymes by multiplex PCR amplification and single base extension.
Knaapen AM; Ketelslegers HB; Gottschalk RW; Janssen RG; Paulussen AD; Smeets HJ; Godschalk RW; Van Schooten FJ; Kleinjans JC; Van Delft JH
Clin Chem; 2004 Sep; 50(9):1664-8. PubMed ID: 15331501
[No Abstract] [Full Text] [Related]
19. Crystal structure of arylamine N-acetyltransferases: insights into the mechanisms of action and substrate selectivity.
Kubiak X; Dairou J; Dupret JM; Rodrigues-Lima F
Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):349-62. PubMed ID: 23289949
[TBL] [Abstract][Full Text] [Related]
20. Arylamine N-acetyltransferases.
Sim E; Westwood I; Fullam E
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):169-84. PubMed ID: 17428149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
